SK bioscienceLtd (A302440) Stock Overview
Engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A302440 from our risk checks.
A302440 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
SK bioscience Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩47,600.00 |
| 52 Week High | ₩61,500.00 |
| 52 Week Low | ₩35,800.00 |
| Beta | 1.22 |
| 1 Month Change | 3.82% |
| 3 Month Change | 23.16% |
| 1 Year Change | -11.03% |
| 3 Year Change | -66.60% |
| 5 Year Change | n/a |
| Change since IPO | -71.83% |
Recent News & Updates
Recent updates
Is SK bioscienceLtd (KRX:302440) Using Debt Sensibly?
May 14
Subdued Growth No Barrier To SK bioscience Co.,Ltd. (KRX:302440) With Shares Advancing 25%
Dec 15Is SK bioscienceLtd (KRX:302440) A Risky Investment?
Jul 11SK bioscienceLtd's (KRX:302440) Weak Earnings May Only Reveal A Part Of The Whole Picture
Mar 23Shareholder Returns
| A302440 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -1.8% | 6.6% | 0.7% |
| 1Y | -11.0% | 24.7% | 4.9% |
Return vs Industry: A302440 underperformed the KR Biotechs industry which returned 24.7% over the past year.
Return vs Market: A302440 underperformed the KR Market which returned 4.9% over the past year.
Price Volatility
| A302440 volatility | |
|---|---|
| A302440 Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in KR Market | 12.1% |
| 10% least volatile stocks in KR Market | 3.0% |
Stable Share Price: A302440 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A302440's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 984 | Jae-Yong Ahn | www.skbioscience.co.kr |
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children.
SK bioscience Co.,Ltd. Fundamentals Summary
| A302440 fundamental statistics | |
|---|---|
| Market cap | ₩3.73t |
| Earnings (TTM) | -₩47.63b |
| Revenue (TTM) | ₩399.83b |
Is A302440 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A302440 income statement (TTM) | |
|---|---|
| Revenue | ₩399.83b |
| Cost of Revenue | ₩349.08b |
| Gross Profit | ₩50.75b |
| Other Expenses | ₩98.38b |
| Earnings | -₩47.63b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -607.75 |
| Gross Margin | 12.69% |
| Net Profit Margin | -11.91% |
| Debt/Equity Ratio | 19.4% |
How did A302440 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/09 20:43 |
| End of Day Share Price | 2025/07/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SK bioscience Co.,Ltd. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyonseok Kim | CLSA |
| Sunghwan Kim | Credit Suisse |
| null null | Credit Suisse |